ALASTAIR THOMPSON to Animals
This is a "connection" page, showing publications ALASTAIR THOMPSON has written about Animals.
Connection Strength
0.265
-
Molecular pathways: preclinical models and clinical trials with metformin in breast cancer. Clin Cancer Res. 2014 May 15; 20(10):2508-15.
Score: 0.020
-
p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy. Br J Cancer. 2013 Dec 10; 109(12):2954-8.
Score: 0.020
-
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 2013 Oct 01; 15(5):R92.
Score: 0.020
-
Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters. Cancer Chemother Pharmacol. 2013 Feb; 71(2):473-80.
Score: 0.018
-
Phenformin as prophylaxis and therapy in breast cancer xenografts. Br J Cancer. 2012 Mar 13; 106(6):1117-22.
Score: 0.017
-
Differential contextual responses of normal human breast epithelium to ionizing radiation in a mouse xenograft model. Cancer Res. 2010 Dec 01; 70(23):9808-15.
Score: 0.016
-
Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy. Br J Cancer. 2010 Jul 13; 103(2):232-8.
Score: 0.016
-
Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Int J Cancer. 2009 Jan 15; 124(2):465-72.
Score: 0.014
-
Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat. 2009 Mar; 114(2):391.
Score: 0.013
-
Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Res. 2008; 10(2):R26.
Score: 0.013
-
Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol. 2008 Jul; 67(1):1-7.
Score: 0.013
-
Thermographic assessment of tumor growth in mouse xenografts. Int J Cancer. 2007 Sep 01; 121(5):1055-8.
Score: 0.013
-
Activity of MDI-301, a novel synthetic retinoid, in xenografts. Anticancer Drugs. 2004 Nov; 15(10):991-6.
Score: 0.011
-
Allele loss from 5q21 (APC/MCC) and 18q21 (DCC) and DCC mRNA expression in breast cancer. Br J Cancer. 1993 Jul; 68(1):64-8.
Score: 0.005
-
ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR. Breast Cancer Res. 2012 Nov 16; 14(6):R148.
Score: 0.005
-
Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. BMJ. 2012 Jul 13; 345:e4447.
Score: 0.004
-
Trans,trans,trans-[PtIV(N3)2(OH)2(py)(NH3)]: a light-activated antitumor platinum complex that kills human cancer cells by an apoptosis-independent mechanism. Mol Cancer Ther. 2012 Sep; 11(9):1894-904.
Score: 0.004
-
Influence of the nuclear membrane, active transport, and cell shape on the Hes1 and p53-Mdm2 pathways: insights from spatio-temporal modelling. Bull Math Biol. 2012 Jul; 74(7):1531-79.
Score: 0.004
-
Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer. Oncotarget. 2012 Jan; 3(1):78-83.
Score: 0.004
-
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell. 2011 Jul 12; 20(1):79-91.
Score: 0.004
-
Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer. Br J Cancer. 1991 Apr; 63(4):609-14.
Score: 0.004
-
An evolutionarily conserved, alternatively spliced, intron in the p68/DDX5 DEAD-box RNA helicase gene encodes a novel miRNA. RNA. 2011 Apr; 17(4):555-62.
Score: 0.004
-
Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome. Oncogene. 2011 Mar 03; 30(9):1046-58.
Score: 0.004
-
Gene expression in oestrogen-dependent human breast cancer xenograft tumours. Br J Cancer. 1990 Jul; 62(1):78-84.
Score: 0.004
-
Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screen. Cell Cycle. 2008 Nov 01; 7(21):3417-27.
Score: 0.003
-
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell. 2008 May; 13(5):454-63.
Score: 0.003
-
A novel form of pRb expressed during normal myelopoiesis and in tumour-associated macrophages. Cell Prolif. 2005 Feb; 38(1):13-24.
Score: 0.003
-
Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res. 2004 Jul 15; 64(14):4875-86.
Score: 0.003
-
Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem J. 1999 Aug 15; 342 ( Pt 1):133-41.
Score: 0.002